Reportlinker Adds Monoclonal Antibodies: 2010

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Monoclonal Antibodies: 2010

http://www.reportlinker.com/p0337384/Monoclonal-Antibodies-2010.html

Introduction

Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines. As a result, there is a strong correlation between a strong MAbs portfolio and overall company

Features and benefits

Strategic dynamics within the sector are broken down by product, company, geography, therapy area, technology type and target.

The outlook for the sector is compared with other sectors of the pharmaceutical industry: small molecules, therapeutic proteins and vaccines.

The impact of biosimilars on future MAb sales growth is evaluated and compared with small molecule brand sales following genericization

Highlights

While Datamonitor believes biosimilar MAbs will make it onto the major markets, the rate of sales erosion of such a biosimilar MAb will be far less than that experienced by a small molecule upon generic entry.

Your key questions answered

Assess the outlook for the monoclonal antibodies sector through to 2015

Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae universe

Appraise the technological developments being made in the sector and see where monoclonal antibody pipelines are being focused

TABLE OF CONTENTS

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this Sector Report 3

PharmaVitae Explorer database 3

Chapter structure 3

Data sourcing 4

Chapter 2 Executive Summary 5

Key findings 5

Introduction to the PharmaVitae company universe 7

The prescription pharmaceutical market to 2015 9

The MAb market will deliver the largest and fastest sales growth across the industry 15

The MAb sector will remain the fastest growing across the pharmaceutical industry 22

Historical market analysis 23

Forecast market analysis 26

Chapter 3 MAb Technology Overview 40

Key findings 40

Introduction 41

Monoclonal antibodies as therapeutic agents 43

Evolution of MAbs 47

Antibody drug conjugates – an alternative 'combination therapy' 55

Bispecific antibodies – is now the time for commercial success? 57

Trifunctional antibodies – successful innovation in a niche indication 58

Ablynx's nanobodies 59

GSK's acquisition of Domantis gives it ownership of DAbs – will the leading Big Pharma player in inhalable drug delivery echo this into the antibody market? 60

Systematic naming of MAbs 61

The MAb timeline—technology evolution 61

Chapter 4 Market Analysis 67

Key findings 67

Introduction 68

MAb market product analysis, 2003–15 72

MAb market company analysis, 2003–15 88

MAb market therapy area analysis, 2003–15 96

MAb market geographic analysis, 2003–15 105

MAb market technology analysis, 2003–15 110

MAb market target analysis, 2003–15 116

Chapter 5 Pipeline Analysis 121

Key findings 121

Introduction 122

MAb pipeline overview 123

Company pipeline analysis 132

Technology pipeline analysis 141

Therapy area pipeline analysis 145

Target pipeline analysis 148

Chapter 6 Key Products 157

Introduction 157

Oncology 158

Immunology & inflammation 171

Central nervous system 183

Infectious diseases 187

Musculoskeletal 191

Other 193

Chapter 7 Appendix 195

References 195

Abbreviations 197

Exchange rates 198

About Datamonitor 199

Datamonitor consulting 199

Disclaimer 201

TABLE OF TABLES

Table 1: PharmaVitae company coverage by peer set 8

Table 2: Molecule type definitions 11

Table 3: General characteristics of small molecule drugs vs. biologics 13

Table 4: Prescription pharmaceutical sales by molecule type ($m), 2009–15 14

Table 5: Overview of a selection of marketed MAbs: technology type and immunogenicity 49

Table 6: Infix nomenclature for MAbs 61

Table 7: Global top five MAb sales ($m), 2002, 2008 and 2014 70

Table 8: Annual revenues of the Big 5 ($m), 2009 and 2015 71

Table 9: Historical MAb product sales ($m), 2003–09 74

Table 10: Forecast MAb product sales ($m), 2009–15 80

Table 11: Historical MAb sales by company ($m), 2003–09 89

Table 12: Forecast MAb sales by company ($m), 2009–15 92

Table 13: Historical MAb sales by therapy area ($m), 2003–09 97

Table 14: Forecast MAb sales by therapy area ($m), 2009–15 100

Table 15: Historical MAb sales by geography ($m), 2003–09 106

Table 16: Forecast MAb sales by geography ($m), 2009–15 107

Table 17: Historical MAb sales by technology ($m), 2003–09 111

Table 18: Forecast MAb sales by technology ($m), 2009–15 112

Table 19: Historical MAb sales by target ($m), 2003–09 117

Table 20: Forecast MAb sales by target ($m), 2009–15 118

Table 21: MAb pipeline overview, 20010 123

Table 22: Count of marketed mAbs by company, 2010 132

Table 23: Count of Phase III-registration MAb players, 2010 134

Table 24: Count of companies with multiple Phase I–II mAb candidates, 2010 137

Table 25: MAb count split by technology type, 2010 141

Table 26: MAb count split by therapy area, 2010 145

Table 27: Detailed product/target analysis of MAbs in late-stage development, 2010 148

Table 28: Novel late-stage MAb targets, 2010 150

Table 29: Novel early-stage MAb targets, 2010 151

Table 30: MAb market key products overview 157

Table 31: Avastin: overview 158

Table 32: Avastin: sales forecast ($m), 2009–15 159

Table 33: MabThera/Rituxan: overview 160

Table 34: MabThera/Rituxan: sales forecast ($m), 2009–15 161

Table 35: Herceptin: overview 162

Table 36: Herceptin: sales forecast ($m), 2009–15 163

Table 37: Erbitux: overview 164

Table 38: Erbitux: sales forecast ($m), 2009–15 165

Table 39: Prolia (oncology): overview 166

Table 40: Prolia (onco): sales forecast ($m), 2009–15 167

Table 41: Vectibix: overview 168

Table 42: Vectibix : sales forecast ($m), 2009–15 169

Table 43: Arzerra: overview 170

Table 44: Humira: overview 171

Table 45: Humira: sales forecast ($m), 2009–15 172

Table 46: Remicade: overview 173

Table 47: Remicade: sales forecast ($m), 2009–15 174

Table 48: Simponi: overview 175

Table 49: Simponi: sales forecast ($m), 2009–15 176

Table 50: Actemra: overview 177

Table 51: Actemra: sales forecast ($m), 2009–15 178

Table 52: Benlysta: overview 179

Table 53: Benlysta: sales forecast ($m), 2009–15 180

Table 54: Stelara: overview 181

Table 55: Stelara: sales forecast ($m), 2009–15 182

Table 56: Tysabri: overview 183

Table 57: Tysabri: sales forecast ($m), 2009–15 184

Table 58: Bapineuzumab: overview 185

Table 59: Bapineuzumab: sales forecast ($m), 2009–15 186

Table 60: Synagis: overview 187

Table 61: Synagis: sales forecast ($m), 2009–15 188

Table 62: Numax: overview 189

Table 63: Numax: sales forecast ($m), 2009–15 190

Table 64: Prolia: overview 191

Table 65: Prolia (musc): sales forecast ($m), 2009–15 192

Table 66: Lucentis: overview 193

Table 67: Lucentis: sales forecast ($m), 2009–15 194

Table 68: Exchange rates, 2010 198

TABLE OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: The total pharmaceutical market outlook, sales ($m) and year-on-year growth rate (%), 2003–15 10

Figure 3: Total sales of the prescription pharmaceutical market ($m), 2003–15 14

Figure 4: Change in annual sales of PharmaVitae universe by molecule type ($m), 2009–15 16

Figure 5: CAGR of PharmaVitae universe by molecule type, 2003-15 17

Figure 6: Launch, core, expiry configuration of small molecules and MAbs, 2009-15 ($m) 18

Figure 7: Volume analysis: small molecule generics versus MAb biosimilars 20

Figure 8: Total sales of the MAb market ($m and %), 2003–15 22

Figure 9: Growth driver/resistor products of historical revenue performance ($m), 2003–09 23

Figure 10: Growth driver/resistor companies of historical revenue performance ($m), 2009–15 25

Figure 11: Total sales of the MAb market ($m), 2003–15 26

Figure 12: Growth driver/resistor products of forecast revenue performance ($m), 2009–15 27

Figure 13: Growth driver/resistor companies of forecast revenue performance ($m), 2009–15 29

Figure 14: Big Pharma peer set net sales growth performance, 2009-15 ($m) 30

Figure 15: The structure of an antibody 42

Figure 16: Types of antibodies 48

Figure 17: Immunogenicity ranges 50

Figure 18: Schematic illustration of antibody fragments 54

Figure 19: MAb timeline – technology shift 62

Figure 20: Total sales of the MAb market ($m and %), 2003–15 69

Figure 21: MAb product sales ($m), 2003–15 72

Figure 22: Growth driver/resistor products of historical revenue performance ($m), 2003–09 76

Figure 23: Growth driver/resistor products of forecast revenue performance ($m), 2009–15 82

Figure 24: MAb sales by company ($m), 2003–15 88

Figure 25: Growth driver/resistor companies of historical revenue performance ($m), 2003–09 90

Figure 26: Growth driver/resistor companies of forecast revenue performance ($m), 2009–15 94

Figure 27: MAb sales by therapy area ($m), 2003–15 96

Figure 28: Growth driver/resistor therapy areas of historical revenue performance ($m), 2003–09 98

Figure 29: Growth driver/resistor therapy areas of forecast revenue performance ($m), 2009–15 101

Figure 30: MAb sales by geography ($m), 2003–15 105

Figure 31: Growth driver/resistor geographies of forecast revenue performance ($m), 2009–15 108

Figure 32: MAb sales by technology ($m), 2003–15 110

Figure 33: Growth driver/resistor technologies of forecast revenue performance ($m), 2009–15 113

Figure 34: MAb sales by target ($m), 2003–15 116

Figure 35: Growth driver/resistor targets of forecast revenue performance ($m), 2009–15 119

Figure 36: Count of marketed mAb players, 2010 133

Figure 37: Count of Phase III pipeline MAb players, 2010 135

Figure 38: Count of companies with multiple Phase I–II mAb candidates, 2010 138

Figure 39: Phase I–III MAb pipeline count split by technology, 2010 142

Figure 40: The stepwise evolution of naked MAb technology 143

Figure 41: Overview of pipeline technology type 144

Figure 42: Phase I–pre-registration mAb count split by therapy area, 2010 146

Figure 43: Count of the most popular novel targets in early-stage development, 2010 156

To order this report:

Pharmaceutical Industry: Monoclonal Antibodies: 2010

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo